 | • レポートコード：MRC2303I0014 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の細胞生存アッセイ市場規模が、予測期間中（2022年〜2027年）に年平均7.7%で成長すると予測しています。本レポートは、細胞生存アッセイの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（消耗品、機器）分析、用途別（創薬＆開発、幹細胞研究、臨床＆診断、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Abcam PLC、Becton Dickinson & Company、Bio-Rad Laboratories、Biotek Instruments、Creative Bioarray、GE Healthcare、Merck KGaA、Perkin Elmer、Promega Corporation、Thermo Fischer Scientific Inc.、Canvax Biotech、Creative Bioarrayなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の細胞生存アッセイ市場規模：製品別 - 消耗品の市場規模 - 機器の市場規模 ・世界の細胞生存アッセイ市場規模：用途別 - 創薬＆開発における市場規模 - 幹細胞研究における市場規模 - 臨床＆診断における市場規模 - その他用途における市場規模 ・世界の細胞生存アッセイ市場規模：地域別 - 北米の細胞生存アッセイ市場規模 アメリカの細胞生存アッセイ市場規模 カナダの細胞生存アッセイ市場規模 メキシコの細胞生存アッセイ市場規模 … - ヨーロッパの細胞生存アッセイ市場規模 ドイツの細胞生存アッセイ市場規模 イギリスの細胞生存アッセイ市場規模 フランスの細胞生存アッセイ市場規模 … - アジア太平洋の細胞生存アッセイ市場規模 中国の細胞生存アッセイ市場規模 日本の細胞生存アッセイ市場規模 インドの細胞生存アッセイ市場規模 … - 中東/南米の細胞生存アッセイ市場規模 南アフリカの細胞生存アッセイ市場規模 ブラジルの細胞生存アッセイ市場規模 アルゼンチンの細胞生存アッセイ市場規模 … - その他地域の細胞生存アッセイ市場規模 ・競争状況 ・市場機会・将来の動向 |
The cell viability assays market is expected to register a CAGR of 7.7% during the forecast period, 2022-2027.
The COVID-19 pandemic has significantly impacted the growth of the cell viability assay market, as most companies have been focusing on developing cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics Inc. revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells Inc. (PSC), received the Food and Drug Administration’s approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. As cell viability assays are essentially used for screening the response of the cells against a drug or a chemical agent, therefore, with the increased use of cell-based therapies, the cell viability assay market is expected to see a surge during the forecast year.
Additionally, according to the study published in Stem Cell Research & Therapy volume on ‘When stem cells meet COVID-19: recent advances, challenges and future perspectives’ published in January 2022, stem cell therapy and stem cell-derived organoid models have got much attention as a new treatment and research method for COVID-19, and stem cells play a role in the battle against COVID-19. With the increase in the need for stem cell therapies, there will be an increase in the need for cell viability assays; hence, the market is expected to grow. Moreover, the growing research and development will open up further opportunities for the market players to launch new products, which is expected to drive market growth during the forecast period.
According to the World Health Organization (WHO), chronic illnesses will account for nearly three-quarters of all fatalities globally by 2020, with ischemic heart disease accounting for 71% of fatalities and diabetes accounting for 70%. Furthermore, as per the Globocan Database, the number of new cases was estimated to increase from 19.3 million to 30.2 million between 2020 and 2040.
Moreover, chronic diseases and conditions are on the rise worldwide. As per the International Diabetes Federation Diabetes Altas, in 2021, nearly 573 million adults globally were living with diabetes worldwide, and the number is expected to reach 643 million by 2030 and 783 million by 2045. As chronic disorders are on the rise, there is a huge demand concerning assays which are helping in the faster treatment and timely detection of the patients’ condition.
In emerging markets, cancer and heart diseases are becoming the main causes of death due to urbanization, sedentary lifestyles, changing diets, rising obesity levels, and widespread availability of tobacco products. In April 2020, Biotek introduced a new cell count and viability starter kit, which can automatically do the process of cell counting and viability measurements in a mammalian cell suspension. Thus, with the growing burden of chronic diseases and the launch of new products, the market is expected to see a surge in the years to come.
However, the lack of professionals and technical experts to run these instruments will challenge the growth of the cell viability assays market in the forecast period mentioned above. Also, the high cost of instruments will obstruct the market growth rate.
Cell Viability Assays Market Trends
Stem Cell Research Segment is Estimated to Register the Fastest Growth Over the Forecast Period
The stem cell research segment is estimated to register the fastest growth, owing to the rising R&D activities and funding from various organizations. For instance, in June 2021, The Morrison Government is investing USD 180 million in ground-breaking medical research projects around Australia to improve the lives of Australians. Funded through the Government’s USD 20 billion Medical Research Future Fund, 106 medical research projects will receive funding to improve health outcomes, including for Australians with cancer, dementia, brain injuries, heart problems, neurofibromatosis, and many others.
Technological advancements will play a significant role in the future, with multiple experiments in pluripotent stem cells being the center for exciting growth. For instance, in April 2022, Researchers at Osaka University developed a biomaterial using stem cells to reverse intervertebral disk (IVD) degeneration, which is associated with back pain and certain spinal issues. The stem cells were induced into chondrocytes — cells producing collagen that supports cartilage tissue. Implanting this biomaterial into a rat model of IVD degeneration brought the spinal mechanical properties back to control levels, and this type of innovation is likely to fuel market growth in future years.
Companies are raising funds to develop stem cell-based therapies to tackle many diseases. For instance, in January 2022, Cellino Biotech, a cell therapy manufacturing company, raised USD 80 million Series A financing round. Cellino plans to expand access to stem cell-based therapies with the intention of building the first autonomous human cell foundry in 2025. As the applications of stem cell technologies in the treatment of diseases have ultimately increased, the overall adoption rate of cell viability assays across the world.
Thus, considering all the aforementioned factors, the market is expected to witness high growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America holds a major share of the cell viability assays market and is expected to witness a similar trend over the forecast period without significant fluctuations. The region is dominating the market, due to various factors, like the increasing incidences of chronic diseases, rise in cancer cases, rise in investment initiatives by governments, and high-quality infrastructure for clinical and laboratory research.
The United States is expected to increase its market share in the future, owing to the increased adoption of cancer therapy and the growing burden of cancers in the United States. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in United States.
For instance, the National Cancer Institute (NCI) stated that the national expenditure on cancer care was expected to reach USD 156 billion by 2020. This factor is expected to boost the market’s future growth. In December 2019, the researchers at the National Eye Institute (NEI) launched a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD), a leading cause of vision loss among people aged 65 years and above. Moreover, in March 2022, Promega Corporation and FUJIFILM Cellular Dynamics, Inc. announced a strategic collaboration to advance novel assay development for drug discovery. Under a multi-year licensing agreement, FUJIFILM Cellular Dynamics will offer a wide range of custom differentiated iPSCs integrated with Promega biosensor and intracellular bioluminescent reporter capabilities for researchers and scientists to use as part of novel assay development in the drug discovery process.
Furthermore, in the United States, there is a rise in the funding for cell-based research, which is expected to propel the overall growth of the cell viability assay market over the forecast period.
Cell Viability Assays Market Competitor Analysis
The cell viability assays market is fragmented and competitive owing to the presence of various small and large market players. Some of the market players are Abcam PLC, Becton Dickinson & Company, Bio-Rad Laboratories, Biotek Instruments, Creative Bioarray, GE Healthcare, Merck KGaA, Perkin Elmer, Promega Corporation, and Thermo Fischer Scientific Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Chronic and Infectious Diseases
4.2.2 Rising Demand for Cell-based Assays in Research
4.2.3 Increasing Focus on the Development of Cell-based Therapeutics
4.3 Market Restraints
4.3.1 Limitations of the Assays
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Consumables
5.1.1.1 Reagents
5.1.1.2 Assay Kits
5.1.1.3 Other Consumables
5.1.2 By Instruments
5.1.2.1 Automated Cell Counters
5.1.2.2 Flow Cytometers
5.1.2.3 Spectrophotometers
5.1.2.4 Other Instruments
5.2 By Application
5.2.1 Drug Discovery and Development
5.2.2 Stem Cell Research
5.2.3 Clinical and Diagnostic Applications
5.2.4 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abcam PLC
6.1.2 Becton Dickinson & Company
6.1.3 Bio-Rad Laboratories
6.1.4 Biotek Instruments
6.1.5 Creative Bioarray
6.1.6 GE Healthcare
6.1.7 Merck KGaA
6.1.8 Perkin Elmer
6.1.9 Promega Corporation
6.1.10 Thermo Fischer Scientific Inc.
6.1.11 Canvax Biotech
6.1.12 Creative Bioarray
7 MARKET OPPORTUNITIES AND FUTURE TRENDS